EXEL vs MRNA
Exelixis, Inc. and Moderna, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | EXEL | MRNA |
|---|---|---|
| Revenue | $2.3B | $1.9B |
| Net income | $782.6M | $-2.8B |
| Gross margin | 96.4% | 55.3% |
| Net margin | 33.7% | −145.2% |
| Return on equity | 35.5% | −28.9% |
| Diluted EPS | $2.78 | −$7.26 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $875.8M | $-2.1B |
| Equity | $2.2B | $8.7B |
| Net debt / equity | · | −0.23× |
| Current ratio | 3.56× | 3.29× |
| Revenue CAGR 5y | 18.6% | 19.3% |
| Profit CAGR 5y | 47.6% | · |
EXEL bills 1.2× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | EXEL | MRNA |
|---|---|---|
| FY2025 | $2.3B | $1.9B |
| FY2024 | $2.2B | $3.2B |
| FY2023 | $1.8B | $6.8B |
| FY2022 | $1.6B | $19.3B |
| FY2021 | $1.4B | $18.5B |
| FY2020 | $987.5M | $803.0M |
| FY2019 | $967.8M | $60.0M |
| FY2018 | $853.8M | $135.1M |
| FY2017 | $452.5M | $205.8M |
| FY2016 | $191.5M | $108.4M |
Bottom line
| Fiscal year | EXEL | MRNA |
|---|---|---|
| FY2025 | $782.6M | $-2.8B |
| FY2024 | $521.3M | $-3.6B |
| FY2023 | $207.8M | $-4.7B |
| FY2022 | $182.3M | $8.4B |
| FY2021 | $231.1M | $12.2B |
| FY2020 | $111.8M | $-747.0M |
| FY2019 | $321.0M | $-514.0M |
| FY2018 | $690.1M | $-384.7M |
| FY2017 | $154.2M | $-255.9M |
| FY2016 | $-70.2M | $-216.2M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$376,126,000 | EXEL |
| FY2024 | −$1,067,299,000 | MRNA |
| FY2023 | −$5,017,792,000 | MRNA |
| FY2022 | −$17,651,938,000 | MRNA |
| FY2021 | −$17,036,030,000 | MRNA |
| FY2020 | +$184,538,000 | EXEL |
| FY2019 | +$907,775,000 | EXEL |
| FY2018 | +$718,758,000 | EXEL |
| FY2017 | +$246,652,000 | EXEL |
| FY2016 | +$83,058,000 | EXEL |
The higher-revenue side has changed between EXEL and MRNA over this period. The gap has widened since the earliest year compared.
10 of 17 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +178.9 pp | EXEL |
| FY2024 | +134.1 pp | EXEL |
| FY2023 | +80.2 pp | EXEL |
| FY2022 | −32.1 pp | MRNA |
| FY2020 | +104.3 pp | EXEL |
| FY2019 | +889.8 pp | EXEL |
| FY2018 | +365.7 pp | EXEL |
| FY2017 | +158.4 pp | EXEL |
| FY2016 | +162.8 pp | EXEL |
The higher net margin has changed hands between EXEL and MRNA over this period.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's net margin has been more volatile than EXEL's over the 9 comparable fiscal years — 245.6 percentage points of standard deviation against 29.2.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between EXEL and MRNA over these 9 fiscal years — EXEL led in 8 and MRNA in 1.
9 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's return on equity has been more volatile than EXEL's over the 7 comparable fiscal years — 64.6 percentage points of standard deviation against 10.0.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between EXEL and MRNA over these 7 fiscal years — EXEL led in 5 and MRNA in 2.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.